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Background: JC polyomavirus (JCPyV) is a widespread human polyomavirus that usually resides latently in its host.
It can be reactivated under immunomodulating conditions and cause Progressive Multifocal Leukoencephalopathy
(PML). Circulating microRNAs (miRNAs) are emerging as promising biomarkers for several pathologies. In this study,
we have investigated whether circulating miRNAs exist that are differentially expressed between JCPyV seropositive
and JCPyV seronegative on the one hand or between JCPyV shedders and JCPyV non-shedders on the other hand.
Methods: Human miRNA expression profiling was performed in a small set of plasma samples obtained from
seronegative subjects, seropositive shedders and seropositive non-shedders. A set of 10 miRNAs was selected for
further analysis in a larger group of samples.
Results: Based on the plasma profiling experiment of 30 samples, 6 miRNAs were selected that were possibly
differentially expressed between seropositive and seronegative subjects and 4 miRNAs were selected that were
possibly differentially expressed between shedders and non-shedders. Subsequently, expression of these 10 selected
miRNAs was assessed in an independent set of 100 plasma samples. Results indicated that none of them were
differentially expressed.
Conclusion: This study could not identify circulating human miRNAs that were differentially expressed between
plasma from JCPyV seropositive and JCPyV seronegative subjects or between JCPyV shedders and JCPyV
non-shedders.
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Progressive Multifocal Leukoencephalopathy (PML) is a
demyelinating disease of the brain caused by reactivation
of the human JC polyomavirus (JCPyV) resulting in lytic
infection of oligodendrocytes [1]. JCPyV is a circular
double-stranded DNA virus with very restricted cellular
tropism, infecting oligodendrocytes, astrocytes, kidney
epithelial cells and peripheral blood cells [2]. It is
thought that infection usually occurs asymptomatically in
childhood, after which the virus remains latent in the
body [3-5]. Under certain immunocompromised condi-
tions, such as treatment with immunomodulatory drugs
or infection with Human Immunodeficiency Virus (HIV),* Correspondence: olagatie@its.jnj.com
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unless otherwise stated.the virus can be reactivated and actively replicate into the
brain, leading to PML. Current diagnostic tools to assess
risk for developing PML consist of the detection of anti-
bodies against VP1, the major capsid protein and the
detection of viral DNA in urine. It has been reported that
50 to 60% of humans are seropositive for JCPyV [6,7].
Approximately one fifth of the population sheds JCPyV
in the urine [8,9]. The prognostic value of both tests (vir-
uria and antibody titer) is being debated [10,11]. Also,
healthy seropositive subjects or subjects who shed virus
in the urine are not at risk of developing PML, indicating
the limited prognostic value of these two tests. Recent
work has also shown that most healthy subjects have
antibodies against peptides derived from the JCPyV
proteome, suggesting that current serology tests might
underestimate the real infection rate [12]. JCPyV is veryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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people but can sometimes be detected in patients treated
with immunomodulatory therapies such as natalizumab
[13]. However, the detection of JCPyV in serum has not
been correlated with progression to PML [14]. Develop-
ment of new tools for stratification of those patients at risk
for developing PML is therefore of great interest.
MicroRNAs (miRNAs) are small, non-coding RNAs
that play an important role in fine-tuning the expression
of specific gene products through translational repres-
sion and/or mRNA degradation [15]. Due to the role
they play in many cellular processes, they are implicated
in many diseases [16,17]. Cellular miRNAs can also be
released in small vesicles and the levels of these extra-
cellular miRNAs in biological fluids have become very
valuable markers of several diseases, such as cancer,
Alzheimer’s disease and diabetes [18-20]. The possible
use of circulating miRNAs as diagnostic marker for
viral infection has also been tested for viruses like in-
fluenza A virus, hepatitis B virus, hepatitis C virus and
Epstein-Barr [21-24].
Whether circulating human miRNAs play a role in
JCPyV related pathology or whether different plasma
miRNA expression patterns can be observed in JCPyV
infected or uninfected subjects, is not known [25]. In
this study we have therefore investigated the plasma
miRNA profile of healthy subjects and assessed whether
certain miRNAs could be identified that were linked to
JCPyV serostatus or urinary viral load.
Methods
Ethics statement
The Ethics Committee [“Commissie voor Medische
Ethiek - ZiekenhuisNetwerk Antwerpen (ZNA) and the
Ethics committee University Hospital Antwerp] approved
the Protocols, and Informed consents, which were signed
by all subjects.
Healthy subject samples
A total of 254 healthy subjects (HSs) were selected in
Belgium for this study: 135 women and 119 men with an
age ranging from 19 up to 66 years (median 42 y, average
42.2 y, 25% percentile 35 y, 75% percentile 50 y). Plasma
samples and urine samples were collected from all these
HSs and stored at −80°C until further processing.
JC polyomavirus viral load assay
Analysis of the urinary viral load was performed as de-
scribed previously [9].
JC polyomavirus VP1 serology assay
The anti- JCPyV antibody assay was performed similarly
to the method described earlier [26]. The assay utilized
Saccharomyces cerevisiae expressed JCPyV VP1 capsidprotein (Abcam, UK). In the ELISA, JCPyV VP1 was
immobilized onto a microtiter plate and blocked to
minimize nonspecific binding. Diluted (1:200) plasma sam-
ples were added to the plate and incubated. The plate was
then washed, and mouse monoclonal anti-human immuno-
globulin G (IgG) (OCD) conjugated with horseradish per-
oxidase (HRP) was added. After a wash step, substrate
solution was added and incubated. The reaction was
stopped with acid solution before measuring the optical
density (OD) values at 450 nm using a plate reader. Sam-
ples were considered positive if OD values were higher than
OD value + 3 SD of the negative control plasma sample.
miRNA expression profiling
miRNA expression profiling was performed by Biogazelle
(Gent, Belgium) using a validated miRNA screening pipe-
line that allows for accurate and sensitive expression ana-
lysis of 755 human microRNAs by means of quantitative
reverse transcriptase PCR (qRT-PCR) with hydrolysis
probe based miRNA assays [27]. Briefly, RNA was isolated
from 200 μL plasma using the miRNeasy kit (Qiagen) ac-
cording to the manufacturer’s instructions. Six μL of total
RNA (representing 40% of total RNA extract) was reverse
transcribed using the Megaplex RT stem-loop primer pool
(Life Technologies), enabling miRNA specific cDNA syn-
thesis of 755 different human miRNAs and small RNA
controls. Subsequently, the Megaplex RT product was
pre-amplified by means of a 12-cycle PCR reaction with
a miRNA specific forward primer and universal reverse
primer to increase detection sensitivity. Diluted pre-
amplified miRNA cDNA was then used as input for a
40-cycle qPCR reaction with miRNA specific hydrolysis
probes and primers (Life Technologies). All reactions
were performed in Taqman arrays on the ViiA7 instrument
(Life Technologies) using the gene maximization strategy.
Quantification cycle (Cq) values were filtered using a
detection cut-off of 32 cycles. Cq values above 32
were considered noise. Data normalization was done in
qbase + following the modified global mean normal-
ization procedure (common targets), as previously de-
scribed [28]. Note that, while Cq-values are log2-based,
normalized expression data is log10-based.
Expression analysis of selected miRNAs
Expression of selected miRNAs was determined similarly
as described above, except that 3 μL of total RNA was
used for reverse transcription. Three stable miRNAs
(hsa-miR-26a, has-miR-30b and mmu-miR-93) were in-
cluded for normalization. Note that, while Cq-values are
log2-based, normalized expression data is log10-based.
Statistical analysis
The differences between groups were assessed using a
Mann-Whitney test. For analysis of miRNA profiling
Table 2 Characteristics of healthy subjects in the miRNA
validation/confirmation study
Median age [range] or number
of subjects (%)
Ab− Ab+ VL+ Ab+ VL−
n = 35 n = 25 n = 40 p-value1
Age 44 [21-65] 51 [24-64] 47 [20-66] 0.115/0.830
Sex Male 16 (45.7) 12 (48.0) 16 (40.0)
Female 19 (54.3) 13 (52.0) 24 (60.0)
1Ab− vs. Ab+ / Ab+VL+ vs. Ab+VL−.
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testing using the Benjamini-Hochberg procedure [29]. Dif-
ferences were considered statistically significant at p < 0.05.
For selection of miRNAs from the profiling study for sub-
sequent confirmation, miRNAs were first selected based
on log2 (fold change) > 0.8 or log2 (fold change) < -0.8 and
were then ranked based on p-value. The 6 miRNAs with
the lowest p-value for comparison of seronegative subjects
vs. seropositive subjects and the 4 miRNAs with the lowest




Urine samples and plasma samples were donated by 254
HSs. All plasma samples were screened for the presence
of anti- JCPyV VP1 antibodies by ELISA. 193 out of
254 HSs (~76.0%) had anti- JCPyV antibodies in their
plasma. All urine samples were screened for the presence
of JCPyV DNA by quantitative PCR. Within the group of
seronegative subjects, none of the HSs had shed viral
DNA into their urine. Within the group of seropositive
subjects, 63 (~24.8%) had shed viral DNA into their
urine. Based on these results, subjects were classified as
seronegative (Ab−), seropositive shedder (Ab+ VL+) or
seropositive non-shedder (Ab+ VL−). Selection of subjects
for miRNA profiling or subsequent validation studies was
done based on these classifications. Characteristics of
subjects selected for the miRNA profiling and for the
miRNA validation/confirmation are shown in Tables 1
and 2, respectively.
Plasma miRNA profiling
We initially performed expression profiling of 755 miR-
NAs in the plasma samples of 30 HSs: 10 Ab−, 10 Ab+
VL+ and 10 Ab+ VL−. A list with all miRNA assays used,
including the miRBase ID and sequence of the corre-
sponding hsa-miR, is provided (Additional file 1: Table S1),
as well as a table with all raw Cq values (Additional file 2:
Table S2). Volcano plots were constructed to provide infor-
mation about the significance and magnitude of expressiveTable 1 Characteristics of healthy subjects in the miRNA
profiling study
Median age [range] or number
of subjects (%)
Ab− Ab+ VL+ Ab+ VL−
n = 10 n = 10 n = 10 p-value1
Age 40 [27-55] 49 [38-59] 37 [26-54] 0.468/0.012*
Sex Male 3 (30.0) 5 (50.0) 5 (50.0)
Female 7 (70.0) 5 (50.0) 5 (50.0)
1Ab− vs. Ab+ / Ab+VL+ vs. Ab+VL−.
*significant difference (p < 0.05).alteration of these miRNAs between 10 seronegative sub-
jects and 20 seropositive subjects on the one hand
(Figure 1) and 10 shedders and 10 non-shedders on the
other hand (Figure 2). 27 miRNAs were found to be differ-
entially expressed between seronegative subjects and sero-
positive subjects (p < 0.05), of which 2 had a fold change > 2
and 4 had a fold change < 0.5. 18 miRNAs were found to be
differentially expressed between shedders and non-shedders
(p < 0.05), of which 4 had a fold change > 2 and 4 had a fold
change < 0.5. However, upon correction for multiple testing
using the Benjamini-Hochberg multiple testing correction
procedure, none of these remained significant. This might
be due to the relatively small sample size, but might also be
indicative of true absence of differentially expressed miR-
NAs between groups.
Validation/confirmation study
Next, we performed qRT-PCR on RNA isolated from
plasma of another 100 HSs: 35 Ab−, 25 Ab+ VL+ and 40
Ab+ VL−. We evaluated the levels of miRNAs that, based
on our profiling study, tended to have different levels of
expression between two groups. This analysis included
miR-184, miR-548a-5p, miR-574-3p, miR-616, miR-1233,
miR-642, miR-140-3p, miR-517b, miR-10b and miR-
380-3p (Figure 3, Tables 3 and 4 and Additional file 3:
Table S3). We found that of these 10 selected miRNAs
only miR-548a-5p and miR-574-3p were differentially
expressed between seronegative subjects (Ab−) and
seropositive subjects (Ab+) with statistical significance
(p < 0.05). However, careful examination of the data
learns that for miR-548a-5p the number of subjects with
detectable levels of this miRNA is too low for proper stat-
istical interpretation. For miR-574-3p the difference be-
tween both groups is statistically significant (p = 0.028)
but since the fold change is only 1.36 this difference is
unlikely to be biologically significant. Between shedders
(VL+) and non-shedders (VL−) none of the miRNAs were
found to be differentially expressed. Also, signal inten-
sities for miR-548a-5p, miR-517b and miR-380-3p were
very low and not detected in most samples. For compre-
hensiveness, it should also be noted that analysis of the
data for gender-driven differences showed that there is a
Figure 1 Comparison of all miRNAs assessed by RT-qPCR analysis of RNA isolated from plasma of JCPyV seronegative subjects (Ab−, n = 10)
or JCPyV seropositive subjects (Ab+, n = 20). A. Volcano plot of pairwise comparisons. The volcano plot displays the relationship between fold-change
and significance between the two groups, using a scatter plot view. The y-axis is the negative log10 of P values (a higher value indicates greater
significance) and the x-axis is the difference in expression between two experimental groups as measured in log2 space. MiRNAs that were selected for
further analysis are indicated in red on the plot. B. Mann-Whitney p-values, adjusted p-values and fold changes (fc) of JCPyV seronegative subjects (Ab−)
vs. JCPyV seropositive subjects (Ab+) for miRNAs with p-value < 0.05. C. Relative expression levels of selected circulating miRNAs in subjects from each
group. Data is presented relative to the mean of the entire population in log10 scale (n = 30).
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miR-642 in males compared to females. However, re-
analysis of the data using gender as a co-variable did not
show any significant difference between seropositive and
seronegative subjects, nor between shedders and non-
shedders (results not shown).Discussion
Several studies indicate that there is a potential role for
circulating miRNA levels as valuable biomarkers for cer-
tain physiological events or disease. It has been shown
in different studies that a large portion of the human
population has been exposed to JCPyV as they carry
Figure 2 Comparison of all miRNAs assessed by RT-qPCR analysis of RNA isolated from plasma of subjects with negative urine JCPyV
Viral Load (VL−, n = 10) or subjects with positive urine JCPyV Viral Load (VL+, n = 10). A. Volcano plot of pairwise comparisons. The volcano
plot displays the relationship between fold-change and significance between the two groups, using a scatter plot view. The y-axis is the negative
log10 of P values (a higher value indicates greater significance) and the x-axis is the difference in expression between two experimental groups
as measured in log2 space. MiRNAs that were selected for further analysis are indicated in red on the plot. B. Mann-Whitney p-values, adjusted
p-values and fold changes (fc) of subjects with positive urine JCPyV Viral Load (VL+) vs. subjects with negative urine JCPyV Viral Load (VL−) for miRNAs
with p-value < 0.05. C. Relative expression levels of selected circulating miRNAs in subjects from each group. Data is presented relative to the mean of
the entire population in log10 scale (n = 30).
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This might raise the question why certain individuals are
seropositive while others are not and whether there is an
intrinsic driving factor that determines susceptibility for
the virus. Within the subpopulation of exposed subjectsa smaller subset excretes large amounts of JCPyV in the
urine [31,32]. It is unclear why some subjects excrete the
virus while others don’t. We therefore wanted to investi-
gate whether miRNA expression levels in plasma are
correlated to JCPyV serology or JCPyV viruria. In a first
Figure 3 Relative expression levels of selected circulating miRNAs in subjects from each group in the validation study (Ab−, Ab+, VL−, VL+).
Data is presented relative to the mean of the entire population in log10 scale (n = 100). * p-value < 0.05.
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small set of samples from seronegative subjects, shedders
and non-shedder. Based on these results, 10 miRNAs were
selected for further analysis and in a subsequent experi-
ment another 100 samples were investigated for these 10
miRNAs. None of them were found to have differentialexpression between seropositive and seronegative subjects
or between shedders and non-shedders. The fact that in the
initial profiling experiment, none of the p-values remained
significant (p < 0.05) after correction for multiple testing
already indicated that the statistical significance of the dif-
ferences observed was possibly caused by chance [33].
Table 3 Number of subjects in the validation study with
detectable levels of selected circulating miRNAs,
Mann-Whitney p-values and fold changes (fc) of Ab− vs.
Ab+ subjects
miRNA Ab− (n = 35) Ab+ (n = 65) p-value fc
Hsa-miR-10b 33 62 0.9856 −0.053
Hsa-miR-140-3p 35 65 0.3456 −0.084
Hsa-miR-380-3p 9 14 0.8293 0.103
Hsa-miR-517b 2 3 0.8633 0.190
Hsa-miR-1233 35 65 0.3779 −0.179
Hsa-miR-184 35 65 0.0697 −0.415
Hsa-miR-548a-5p 2 14 0.0410 1.393
Hsa-miR-574-3p 35 65 0.0280 0.447
Hsa-miR-616 24 56 0.6294 1.678
Hsa-miR-642 26 45 0.3721 −0.458
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positive and seronegative subjects is at first sight not
that surprising as the presence or lack of antibodies
against JCPyV might simply be explained by the fact that
some subjects have and some other subjects have not
been exposed to the virus. The lack of differential
miRNA patterns between both groups might indeed be
indicating that a subject’s JCPyV serostatus is driven by
viral exposure and is only limitedly influenced by the
background of the subject itself. One should however be
mindful that JCPyV VP1 serology might actually under-
estimate real infection rates [12]. As a consequence this
study would then effectively be comparing two groups of
infected individuals, which may account for the lack of a
difference. It should also be mentioned that to date 12
human polyomaviruses have been identified, all with highTable 4 Number of subjects in the validation study with
detectable levels of selected circulating miRNAs,
Mann-Whitney p-values and fold changes (fc) of VL− vs.
VL+ subjects
miRNA VL− (n = 40) VL+ (n = 25) p-value fc
Hsa-miR-10b 37 25 0.576 −0.196
Hsa-miR-140-3p 40 25 0.736 −0.019
Hsa-miR-380-3p 6 8 0.083 −1.164
Hsa-miR-517b 2 1 0.867 0.155
Hsa-miR-1233 40 25 0.504 0.108
Hsa-miR-184 40 25 0.325 0.190
Hsa-miR-548a-5p 11 3 0.157 1.470
Hsa-miR-574-3p 40 25 0.793 −0.139
Hsa-miR-616 35 21 0.438 0.607
Hsa-miR-642 27 18 0.396 1.635seroprevalence, making it likely that an individual is in-
fected with several human polyomaviruses [34-37]. The
differential plasma miRNA profile that may exist be-
tween JCPyV seropositive and seronegative individuals
may therefore be masked by infection with other hu-
man polyomaviruses. Further studies might therefore
require full human polyomavirus serotyping of the sub-
jects examined.
The lack of different miRNA patterns between shed-
ders and non-shedders on the other hand was more sur-
prising as both groups have been exposed to the virus
(both are seropositive) but only shedders appear to have
active replication of the virus. One might have expected
that some difference in biological or genetic background
is needed to explain this observation. However, although
limited to the analysis of circulating miRNAs only, our
data presented in this study show this is not the case.
There is one observation that might be of interest for
further study, even though it is not JCPyV related. Based
on the analysis of hsa-miR-642, the population of 100
healthy subjects clearly can be separated in 2 groups,
one with relatively high levels of hsa-miR-642 and one
with low or undetectable levels of hsa-miR-642. Also,
more female subjects appear to fall in the low expression
group compared to male subjects. As it has been shown
that hsa-miR-642 is an adipocyte-specific miRNA, it will
be of interest to see whether this hsa-miR-642 based
clustering is linked to specific metabolic parameters,
such as Body Mass Index or blood cholesterol and fatty
acids levels, or insulin resistance [38].
It should also be noted that only 755 miRNAs were
analyzed in this study and it cannot be excluded that dif-
ferential expression might be present for other miRNAs
that were not analyzed here. Also, differences in circulat-
ing miRNAs that are expressed at low levels may have
been missed. Other techniques that are not limited in
the number of miRNAs, such as small RNA sequencing
using deep sequencing platforms, have been shown to be
very useful to investigate this [39,40]. Besides the use of
a different analytical platform, one might also consider
using PAXgene blood instead of plasma. This might
show a totally different picture as it does not only in-
clude circulating miRNAs but also cellular miRNAs
present in blood cells [41,42].
Although this study did not result in the identification
of circulating miRNAs related to JCPyV infection, circu-
lating miRNAs might still hold potential as biomarkers
for PML progression in immunocompromised patients.
It will therefore be of interest to investigate the miRNA ex-
pression profile of samples obtained from PML patients.
Conclusions
Based on the experiments described in this work, we
conclude that no differences in circulating human miRNAs
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http://www.virologyj.com/content/11/1/41can be observed between JCPyV seropositive subjects
and JCPyV seronegative subjects on the one hand and
between JCPyV shedders and non-shedders on the other
hand.
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